In Regard to Nantavithya et al

To the Editor: We read the interesting results from a phase 2 randomized study comparing the toxicity and efficacy of stereotactic body proton therapy (SBPT) and stereotactic body radiation therapy (SBRT) for high-risk medically inoperable early-stage non-small cell lung cancer (NSCLC) by Nantavithya et al (1). Although their study was closed early because of poor accrual and insurance issues, a total of 19 patients receiving 50 Gy (relative biologic effectiveness) in 4 fractions were included for analysis.

https://ift.tt/2IVTVEg